Westpac Banking Corp Has $2.49 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Westpac Banking Corp raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 83.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,560 shares of the biopharmaceutical company's stock after acquiring an additional 4,819 shares during the period. Westpac Banking Corp's holdings in Alnylam Pharmaceuticals were worth $2,485,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $1,045,822,000. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $577,941,000. Raymond James Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $61,160,000. Finally, Proficio Capital Partners LLC boosted its holdings in Alnylam Pharmaceuticals by 25,929.6% in the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after acquiring an additional 192,916 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY traded down $8.70 during trading on Tuesday, reaching $224.25. The stock had a trading volume of 565,488 shares, compared to its average volume of 820,429. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a 50 day moving average of $258.16 and a two-hundred day moving average of $259.83. The firm has a market capitalization of $29.17 billion, a price-to-earnings ratio of -103.35 and a beta of 0.30.

Remove Ads

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company's stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 in the last 90 days. Company insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Royal Bank of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. Bank of America raised their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Finally, Sanford C. Bernstein lowered their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $316.25.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.